Inventor
DEGRADO WILLIAM F
US33 patents
⚠️ This page may combine multiple inventors who share the name “DEGRADO WILLIAM F”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
DEGRADO WILLIAM F
15 patentsUS8236800B2Aug 7, 2012
Facially amphiphilic polymers and oligomers and uses thereof
DEGRADO WILLIAM F25 citations92
US8278309B2Oct 2, 2012
Synthetic mimetics of host defense and uses thereof
DEGRADO WILLIAM F16 citations90
US8455490B2Jun 4, 2013
Facially amphiphilic polymers and oligomers and uses thereof
DEGRADO WILLIAM F13 citations83
US8222456B2Jul 17, 2012
Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
DEGRADO WILLIAM F7 citations83
US8975262B2Mar 10, 2015
Synthetic mimetics of host defense and uses thereof
DEGRADO WILLIAM F10 citations82
US8716530B2May 6, 2014
Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
DEGRADO WILLIAM F4 citations72
US9301950B2Apr 5, 2016
Adamantane analogs
DEGRADO WILLIAM F2 citations63
US8569284B2Oct 29, 2013
Inhibitors of the influenza A virus M2 proton channel
DEGRADO WILLIAM F3 citations63
US8557836B2Oct 15, 2013
Spiro-piperidine inhibitors
DEGRADO WILLIAM F3 citations63
US8258159B2Sep 4, 2012
Inhibitors of the α2β1/GPIa-IIa integrin
DEGRADO WILLIAM F5 citations58
US9464075B2Oct 11, 2016
Influenza A virus inhibition
DEGRADO WILLIAM F0 citations52
US9453005B2Sep 27, 2016
Inhibition of influenza M2 proton channel
DEGRADO WILLIAM F0 citations52
US9241917B2Jan 26, 2016
Facially amphiphilic polymers and oligomers and uses thereof
DEGRADO WILLIAM F0 citations51
US8889163B2Nov 18, 2014
Facially amphiphilic polymers as anti-infective agents
DEGRADO WILLIAM F0 citations51
US8987306B2Mar 24, 2015
Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
DEGRADO WILLIAM F0 citations37
UNIV PENNSYLVANIA
7 patentsUS7173102B2Feb 6, 2007
Facially amphiphilic polymers as anti-infective agents
UNIV PENNSYLVANIA34 citations92
US7590517B2Sep 15, 2009
Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
UNIV PENNSYLVANIA30 citations89
US7910609B2Mar 22, 2011
Inhibitors of integrin alpha2beta1 with modified urea moiety
UNIV PENNSYLVANIA11 citations78
US6677431B2Jan 13, 2004
Design, preparation, and properties of antibacterial β-peptides
UNIV PENNSYLVANIA9 citations68
US8349791B2Jan 8, 2013
Polypeptides that bind membrane proteins
UNIV PENNSYLVANIA3 citations57
US9403777B2Aug 2, 2016
Inhibitors of the influenza A virus M2 proton channel
UNIV PENNSYLVANIA0 citations52
US9884832B2Feb 6, 2018
Inhibitors targeting drug-resistant influenza A
UNIV PENNSYLVANIA0 citations39
UNIV CALIFORNIA
6 patentsUS10214522B2Feb 26, 2019
Anti-alphavbeta1 integrin inhibitors and methods of use
UNIV CALIFORNIA15 citations83
US10131658B2Nov 20, 2018
Anti-alphavbeta1 integrin compounds and methods
UNIV CALIFORNIA15 citations81
US10836720B2Nov 17, 2020
Inhibitors of integrin alpha 5 beta 1 and methods of use
UNIV CALIFORNIA2 citations60
US11643388B2May 9, 2023
Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
UNIV CALIFORNIA0 citations49
US11597727B2Mar 7, 2023
Inhibitors of integrin alpha 2 beta 1 and methods of use
UNIV CALIFORNIA0 citations49
US11530180B2Dec 20, 2022
Alpha-5 beta-1 inhibitors
UNIV CALIFORNIA0 citations49
DU PONT MERCK PHARMA
3 patentsUS5563158AOct 8, 1996
Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
DU PONT MERCK PHARMA26 citations92
US5635477AJun 3, 1997
Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
DU PONT MERCK PHARMA29 citations91
US5703092ADec 30, 1997
Hydroxamic acid compounds as metalloprotease and TNF inhibitors
DU PONT MERCK PHARMA58 citations90